Prostate-Specific Antigen levels among men living in a rural community in Kogi state, Nigeria
DOI:
https://doi.org/10.4314/wnjms.v8i2.5Keywords:
Prostate cancer, screening, rural community, Kogi state, NigeriaAbstract
Introduction: The burden of prostate cancer in Nigeria is the highest in Africa, with a handful of studies reporting the prevalence of the disease mostly from urban areas. There is a paucity of data on the disease prevalence in men in rural underserved areas of Nigeria, which make up over 45 % of the >200 million population. This study, therefore, investigated the Prostate-Specific Antigen levels among Men living in a rural community in Kogi state, Nigeria.
Methods: In this descriptive cross-sectional community-based study, a non-probability convenience sampling technique was used to select the participants. As part of the cancer awareness campaign of the Dove-Haven Foundation, blood samples from 33 men were screened for Prostate-Specific Antigen (PSA) in the rural areas of Yagba East Local Government Area of Kogi state, Nigeria.
Results: The mean age of participants was 52.5 years. The range of PSA values obtained was 0.1 - 77 with mean value of 4.06. Of the participants tested, 8.8 % had PSA levels of >4 ng/mol, while 2.9 % had PSA levels of >76 ng/mol. These participants have been recommended for direct rectal exams to rule out early prostate cancer.
Conclusion: Our result showed that there were high levels of Prostate-Specific Antigen among the Men living in this rural community. This underscores the importance of prostate screening exercises in rural underserved communities to enhance early detection and reduce prostate cancer burden.
References
Leslie S, Soon-Sutton TL, Sijjad H, Siref LP. Prostate Cancer. 2023 Statpearls Publishing, Treasure Island 2023. http://www.ncbi.nlm.nih.gov/books/nbk470550/
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019; 10(2):63-89. doi:10.14740/wjon1191
Bosland MC, Nettey OS, Phillips AA, Anunobi CC, Akinloye O, Ekanem IA, et al. Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report. Prostate. 2021; 81(9):553-559. doi:10.1002/pros.24133
Abdus-Salam AA, Jimoh MA, Folasire AM, Ntekim AI, Ojo OT, Ehiedu CG, et al. Sociodemographic and clinicopathologic characteristics of patients treated with high dose rate prostate brachytherapy in Nigeria. Ecancermedicalscience. 2024; 18:1740. doi:10.3332/ecancer.2024.1740.
Ugwumba FO, Nnabugwu II. Prostate cancer characteristics: A descriptive analysis of clinical features at presentation in the last decade in a black African community. Ann Afr Med. 2022; 21(2):153-157. doi:10.4103/aam.aam_101_20
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-990. doi:10.1056/NEJMoa1113135
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024; 86(2):148-163. doi:10.1016/j.eururo.2024.03.027
Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S, Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 2016; 4(3):118-24. doi: 10.1016/j.prnil.2016.07.001. 2016; 4(3):118-124. doi:10.1016/j.prnil.2016.07.001
Enemugwem RA, Eze BA, Ejike, U, Asuquo EO, Tobin A. Prostate cancer screening: assessment of knowledge and willingness to screen among men in Obio Akpor LGA, Rivers State, Nigeria. Afr J Urol. 2019; 25(11): 1-4. https://doi.org/10.1186/s12301-019-0010-5
Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. 1999; 91(3):159-164..
Akinremi TO, Ogo CN, Olutunde AO. Review of prostate cancer research in Nigeria. Infect Agent Cancer. 2011; 6 (Suppl 2):S8. doi:10.1186/1750-9378-6-S2-S8
American Cancer Society 2021. Screening Tests for Prostate Cancer. [Online]. Available at https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/tests.html (Date Accessed: May 22, 2024).
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384:2027–2035.
Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017; 123(4):592–599
Access to Financial Services in Nigeria survey. EFInA: Enhancing Financial Innovation and Access. Access to Financial Services in Nigeria survey 2020. 2023. [Online]. Available at https://a2f.ng/wp-content/uploads/2024/07/A2F-2023-SURVEY-REPORT-1.pdf. (Date Accessed: October 4, 2025).
Kress DH, Su Y, Wang H. Assessment of Primary Health Care System Performance in Nigeria: Using the Primary Health Care Performance Indicator Conceptual Framework. Health Syst Reform. 2016; 2(4):302-318. doi:10.1080/23288604.2016.1234861.
City Population. Map. [Online]. Available at https://citypopulation.de/en/nigeria/admin/NGA023__kogi/. (Date Accessed: December 5, 2022).
Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 2017; 167(7):449-455. doi:10.7326/M16-2586
Okafor EN, Okonkwo IN, Nubila NI, Ugonabo MC. Need for Age-Specific Prostate-Specific Antigen Reference Intervals in a Nigerian Population. Nigerian Journal of Clinical Practice. 2023; 26(10):1430-1435, doi: 10.4103/njcp.njcp_1643_21.
Etawo US, Ekeke ON, Miaba AB. Prospective study of sex hormone levels among prostate cancer patients attending the University of Port Harcourt Teaching Hospital. Niger Health J. 2012; 12:29–42.
Aisuodionoe-Shadrach OI, Oluwole OP, Magnus EF, Ehighibe AP. Incidence of hospital-based screen-detected prostate cancer in Abuja, Nigeria. New Nigerian Journal of Clinical Research. 2016; 5(8):51.
Esomonu U, Obun C, Ude R, Igwe S, Esomchi C, Ogolekwu S. Prevalence of benign prostatic hyperplasia and prostate cancer among suburban residents in Southern Nigeria. Afr J Urol. 2024; 30: 66. https://doi.org/10.1186/s12301-024-00470-x
Ogunbiyi OJ. Impact of health system challenges on prostate cancer control: health care experiences in Nigeria. Infect Agent Cancer. 2011; 6 Suppl 2(Suppl 2): S5. doi: 10.1186/1750-9378-6-S2-S5.
Nigerian Population Commission: Nigeria Demographic and Health Survey 2008: www.nationalpopulation.gov.ng. [Online]. Available at https://data.worldbank.org/indicator/SP.RUR.TOTL?locations=NG (Date Accessed: December 5, 2022).
Reed HE, Mberu BU. Capitalizing on Nigeria's demographic dividend: reaping the benefits and diminishing the burdens. Etude Popul Afr. 2014; 27(2): 319-330. doi: 10.11564/27-2-477.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Western Nigeria Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
